LivaNova PLC (NASDAQ:LIVN) Holdings Trimmed by KBC Group NV

KBC Group NV lowered its position in shares of LivaNova PLC (NASDAQ:LIVN) by 56.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,487 shares of the company’s stock after selling 56,441 shares during the quarter. KBC Group NV’s holdings in LivaNova were worth $1,708,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. PNC Financial Services Group Inc. boosted its stake in LivaNova by 29.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company’s stock valued at $292,000 after buying an additional 1,424 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of LivaNova by 2,299.7% in the 1st quarter. GAMMA Investing LLC now owns 8,759 shares of the company’s stock valued at $344,000 after purchasing an additional 8,394 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in shares of LivaNova in the 4th quarter valued at $2,772,000. Envestnet Asset Management Inc. boosted its position in shares of LivaNova by 15.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company’s stock valued at $2,034,000 after purchasing an additional 5,850 shares during the period. Finally, Schonfeld Strategic Advisors LLC boosted its position in shares of LivaNova by 147.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company’s stock valued at $4,582,000 after purchasing an additional 58,911 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Wall Street Zen lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 8th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of LivaNova in a research report on Tuesday, May 13th. Wolfe Research upgraded LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price target for the company in a research report on Tuesday, May 20th. Barclays decreased their price target on LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a research report on Thursday, May 8th. Finally, Robert W. Baird increased their price target on LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, LivaNova presently has a consensus rating of “Buy” and a consensus price target of $59.29.

LivaNova Trading Up 0.1%

Shares of NASDAQ LIVN opened at $46.13 on Friday. LivaNova PLC has a one year low of $32.48 and a one year high of $57.35. The firm has a market capitalization of $2.52 billion, a PE ratio of -11.28 and a beta of 0.90. The company has a current ratio of 1.58, a quick ratio of 1.37 and a debt-to-equity ratio of 0.53. The business has a 50-day moving average price of $43.46 and a two-hundred day moving average price of $43.36.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.